Loading stock data…
Insulet Corporation (PODD)
$163.26+4.88 (+3.08%)
Market ClosedLast close Jul 24
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Insulet Corporation in the Healthcare sector is trading at $163.26 with a market capitalization of $10.0B. Wall Street consensus targets $238.22 (23 analysts), implying a +45.9% move over the next 12 months. The stock is currently near its 52-week low of $138.79, remaining 30.8% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +45.9% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $761.70M↓ | $783.80M↑ | $706.30M↑ | $649.10M↑ | $569.00M |
| Gross Profit | $529.10M↓ | $568.60M↑ | $510.10M↑ | $452.20M↑ | $409.00M |
| Operating Income | $122.20M↓ | $146.30M↑ | $117.70M↓ | $121.10M↑ | $88.70M |
| Net Income | $91.10M↓ | $101.60M↑ | $87.60M↑ | $22.50M↓ | $35.40M |
Peer Comparison
JNJUNHPFE
Fundamentals
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin de...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$10.04B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
33.94
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.20
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
23.25%
Volume
Today's trading volume
1.14M
Recent News
Insulet's Q2 2026 Earnings: What to Expect
Insulet will release its second-quarter earnings next month, and analysts anticipate a double-digit bottom-line growth.
Goldman Flags 3 AI-Resistant Investment Themes to Watch
Last week’s chip-led selloff showcased just how quickly sentiment on AI can shift and drive a rotation out of tech stocks. Goldman Sachs outlined three investment themes to play for investors worried about AI overexposure in their portfolio.
1 Healthcare Stock to Target This Week and 2 We Brush Off
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 13.3% over the past six months, topping the S&P 500 by 2.5 percentage points.
3 Quality Compounders on Our Buy List
Quality compounders are well-oiled machines. Their competitive advantages allow them to make profits consistently and reinvest them into projects that generate even more profits, creating a virtuous cycle of returns.
Insulet Corporation (PODD) Fell Along with Broad Medtech Sector
ClearBridge Investments, a global equity manager, recently published second-quarter 2026 commentary for its “SMID Cap Growth Strategy”. A copy can be downloaded here. Small and mid-cap (SMID) growth equities experienced the strongest quarter in recent memory, with the Russell 2500 Growth Index rising 24.0%, driven by enthusiasm for AI infrastructure and higher-beta momentum stocks. The […]